- NeuroQuant® ARIA
Accurate quantification, visualization, and longitudinal tracking of lesions to support ARIA surveillance
NeuroQuant® 5.0 enables precise segmentation and quantification of T2*GRE, SWI, and FLAIR lesions, supporting ARIA-E and ARIA-H surveillance and grading. This advanced functionality facilitates longitudinal tracking of lesion dynamics to assist with the assessment of patients receiving anti-amyloid therapies.
AI-Assisted Monitoring for Alzheimer's Disease Patients on Anti-Amyloid Immunotherapies
NeuroQuant 5.0 offers comprehensive FLAIR and 2D T2* GRE/SWI lesion segmentation and quantification, enabling physicians to accurately monitor lesion dynamics—including lesion count, max diameter, and volume—in patients receiving anti-amyloid therapies, which supports informed decision-making and monitoring over time.
Benefits
Lesion quantification
Accurate segmentation and longitudinal tracking of FLAIR and T2*GRE/SWI lesions
OEM protocol standardization
To ensure reproducible outcomes and accuracy over time
Longitudinal disease tracking
Monitor lesion counts and maximum diameters over time, with comparisons to baseline and prior timepoints
NeuroQuant® ARIA reports
Reports that provide quantitative insights to support physicians in their clinical assessment of ARIA through FLAIR and T2*GRE/SWI lesion quantification, characterizing relevant findings, tracking changes over time, and assisting in ARIA surveillance.
ARIA-H Report
NeuroQuant ARIA-H report provides analysis and tracking of T2*GRE/SWI lesions including microhemorrhage and superficial siderosis counts and locations
ARIA-E Report
NeuroQuant ARIA-E Report provides analysis and tracking of FLAIR lesions compared with a baseline study, identifying potential sites of involvement, their location and size.
